Oliver Luxxe Assets LLC Raises Stock Holdings in CVS Health Corporation $CVS

Oliver Luxxe Assets LLC raised its stake in CVS Health Corporation (NYSE:CVS) by 26.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 134,539 shares of the pharmacy operator’s stock after buying an additional 28,052 shares during the quarter. CVS Health accounts for about 2.0% of Oliver Luxxe Assets LLC’s holdings, making the stock its 3rd biggest holding. Oliver Luxxe Assets LLC’s holdings in CVS Health were worth $13,918,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CVS. Norges Bank acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $1,666,265,000. Wellington Management Group LLP raised its position in CVS Health by 193.2% in the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after purchasing an additional 12,233,675 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in CVS Health by 1,020.7% during the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock worth $347,984,000 after buying an additional 4,412,882 shares in the last quarter. Amundi boosted its position in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of CVS Health by 44.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock valued at $446,703,000 after buying an additional 1,899,932 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CVS has been the topic of several research reports. Wells Fargo & Company upped their price target on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Piper Sandler reissued an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Barclays upped their target price on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings upgraded shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Finally, Royal Bank Of Canada increased their price objective on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $106.46.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 3,372,000 shares of company stock valued at $317,473,598 over the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Trading Down 0.6%

NYSE:CVS opened at $95.61 on Friday. CVS Health Corporation has a 1-year low of $63.30 and a 1-year high of $110.68. The business’s 50-day moving average price is $102.26 and its two-hundred day moving average price is $87.74. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $122.28 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 0.87 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s payout ratio is currently 70.37%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported second-quarter adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. Management raised its 2026 adjusted EPS outlook to $7.90–$8.10, supported by improving performance at Aetna and strength in the retail business. CVS Health earnings and GLP-1 partnership article
• Positive Sentiment: The company expanded its collaboration with Eli Lilly on GLP-1 weight-management treatments. The initiative could help CVS combine its pharmacy, insurance and care-delivery assets to capture a larger role in the growing obesity-treatment market. CVS GLP-1 strategy article
• Positive Sentiment: Analysts have modestly increased their fair-value estimate for CVS from $111.92 to $114.88, reflecting more constructive views following the earnings results, although execution and policy risks remain. CVS fair value estimate article
• Neutral Sentiment: Healthcare was among the sectors receiving defensive ETF inflows, which may provide some broader investor support for CVS, but the flows were concentrated largely in broad-market funds, Treasuries and gold rather than being a company-specific catalyst. Weekly ETF flows article
• Negative Sentiment: Executives warned that Caremark pharmacy-benefit-management membership could decline in 2026 and that changes involving the 340B drug-pricing program may remain a headwind into 2027. These comments overshadowed the earnings beat and guidance increase by raising concerns about future revenue and profit growth. CVS earnings call risks article

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.